Abstract:OBJECTIVE:The purpose of this phase I/II study is to investigate the safety/toxicity profile of weekly administration of docetaxel in combination with cisplatin for the chemo-naive patients with advanced non-small cell lung cancer (NSCLC), and to evaluate the efficacy of this regime. METHODS:In phase I trial, 15 patients were included. IV infusion of escalating doses of docetaxel consisting of four levels from 25 to 40 mg/m2 (25, 30, 35, 40 mg/m2) on D1, 8, 15 and cisplatin of 75 mg/m2 on D1 was administered. The regime was repeated every 4 weeks. Blood samples were obtained on D1, 15 in the first cycle to measure the PK. Dose limiting toxicity (DLT) was determined in cycle 1 and defined as any grade 3 non-hematologic toxicity which could not be reverted into grade less than grade 2 within 4 days or any grade 4 hematologic toxicity. Eighty-three patients completed their phase II study with administration of docetaxel at a dose of 35 mg/m2 based on the data of phase I trial. RESULTS:In the phase I trial, grade 3/4 neutropenia was mainly observed in patients who received docetaxel of 40 mg/m2 (level 4) with one patient suffering from an infection signifying dose limiting toxicity (DLT). Non-hematological toxicities including nausea/vomiting, alopecia, fluid retension and asthenia were tolerable. Based on these data, the maximum tolerence dose (MTD) did not reach the level of weekly giving docetaxel at a dose of 40 mg/m2 in combination with cisplatin 75 mg/m2 every 4 weeks. The pharmacokinetic/dynamics results There was no statistically significant difference between clearance value among the 4 dose levels of docetaxel from 25 to 40 mg/m2 when measured by Cmax and AUC. The pharmacokinetics of docetaxel was not influenced by the presence of co-administration of cisplatin when compared D1 with D15 as based on CmaxN, AUCN and CL. In the phase II trial, totally 83 patients received 216 cycles of chemotherapy. One CR (complete response) and 22 PR (partial response) were achieved with an objective response rate of 27.7% in this series and 30.7% in the evaluable patients. The 1-year survival was 48.6% with a median survival of 10.7 months (range: 3-34 months). Hematologic toxicities were the major side effects, though most were mild; grade III/IV neutropenia developed in 15%. The common non-hematologic toxicities were nausea, vomiting and asthenia. CONCLUSION:Weekly consecutive administration of docetaxel on D1, 8, 15 for 3 weeks plus cisplatin on D1 is tolerable and effective with minimal myelosuppression in chemo-naive patients with advanced NSCLC.

Weekly Paclitaxel/Docetaxel Combined with A Platinum in the Treatment of Advanced Non-Small Cell Lung Cancer: A Study on Efficacy, Safety and Pre-Medication

A Study of Weekly Docetaxel and Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer.

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

Efficacy of biweekly-regimens of paclitaxel liposome combined with nedaplatin on advanced non-small cell lung cancer

[A Phase II Prospective Randomized Controlled Trial of Weekly Paclitaxel Combined with S-1 or Fluorouracil for Advanced Gastric Carcinoma].

A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

Outcome of Advanced Nonsmall Cell Lung Cancer Patients Receiving Gemcitabine and Weekly Paclitaxel As First-Line Treatment

[A Multicenter Randomized Clinical Trial of Weekly Paclitaxel and Carboplatin Vs Three Weeks Paclitaxel and Carboplatin As First Line Chemotherapy in Epithelial Ovarian Cancer].

An Analysis on Weekly Docetaxel Combined with Cisplatin for 46 Cases with Non-Small Cell Lung Cancer

Safety Analysis of Weekly Paclitaxel Plus S-1 Versus Paclitaxel Plus 5-Fluorouracil/calcium Folinate As First-Line Therapy in Advanced Gastric Cancer: a Multicenter Open Random Phase II Trial

Weekly Albumin-Bound Paclitaxel/cisplatin Versus Gemcitabine/cisplatin As First-Line Therapy for Patients with Advanced Non-Small-cell Lung Cancer: A Phase II Open-Label Clinical Study

A Phase II Trial of Weekly Paclitaxel and High-Dose 5-Fluorouracil Plus Leucovorin in Patients with Chemotherapy-Pretreated Metastatic Breast Cancer.

Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study.

Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study.

Effects of liposomal paclitaxel and paclitaxel in treatment of non-small-cell lung cancer(64 patients) and breast cancer(62 patients)

[A Randomized Phase I/II Trial to Compare Weekly Usage with Triple Weekly Usage of Paclitaxel in Concurrent Radiochemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer].

Weekly Paclitaxel Improved Pathological Response of Primary Chemotherapy Compared with Standard 3 Weeks Schedule

A Phase Ii Study of Weekly Nanoparticle Albumin-Bound Paclitaxel Combined with Cisplatin in Patients with Metastatic Breast Cancer

Phase I Study to Determine the Mtd of Paclitaxel Given Three Times Per Week During Concurrent Radiation Therapy for Stage Iii Non-Small Cell Lung Cancer

Assessing the Clinical Outcome of Nab-Paclitaxel in Chinese Patients with Advanced Non-Small-cell Lung Cancer.